Exam 2 Prototypes Flashcards
diphenhydramine (Benadryl) Pharmacological Class
H-1 receptor blocker
diphenhydramine (Benadryl) Indications
Allergies motion sickness insomnia pruritus Parkinson's Disease
diphenhydramine (Benadryl) MOA
H-1 receptor antagonist
diphenhydramine (Benadryl) Contraindications
elderly more likely to experience delirium, dizziness, inc HR. Children more likely to have paradoxical excitation
diphenhydramine (Benadryl) Adverse Effects
drowsiness (develop tolerance to this), dry mouth, inc. HR (anticholinergic effects
diphenhydramine (Benadryl) Other Considerations
avoid concurrent use w/ other CNS depressants (opioids, alcohol, etc.)
fluticasone(Flonase) pharmacological class
corticosteroids
fluticasone(Flonase) Indications
allergic rhinitis, asthma(can be given as an inhaler)
fluticasone(Flonase) MOA
decreases inflammation in nasal mucosa
fluticasone(Flonase) adverse effects
burning sensation when spraying, epistaxis (nose bleed)
oxymetazoline (Afrin) Pharmacological class
sympathomimetic
oxymetazoline (Afrin) Indications
allergic rhinitis, nosebleeds
oxymetazoline (Afrin) MOA
alpha 1-adrenergic agonist (causes vasoconstriction of blood vessels in nasal mucosa and drying of mucous membranes)
oxymetazoline (Afrin) adverse effects
rebound congestion, dry/stinging nasal mucosa
atropine adverse effects
Dry mouth, constipation, urinary retention, tachycardia, blurred vision
atropine pharmacological class
anticholinergic
atropine indications
GI hypermotility, suppress secretions during surgery, symptomatic bradycardia, pupil dilation for exam, antidote for poisoning with nerve gas or organophosphates (insecticides)
atropine contraindications
Clients with glaucoma
atropine MOA
Blocks cholinergic (muscarinic) receptors, causing increased heart rate, decreased GI motility, mydriasis, bronchodilation, and decreased secretion from glands (salivation)
spironolactone pharmacological class
Aldosterone antagonist
spironolactone indications
Heart failure , edema with liver failure, HTN, hyperaldosteronism
spironolactone MOA
Inhibits aldosterone, increasing the secretion of water and sodium while decreasing the excretion of potassium
spironolactone adverse effects
Hyperkalemia, hyponatremia, diarrhea, gynecomastia
spironolactone nursing implications
Monitor urine output, BP, potassium levels; educate clients to avoid foods high in potassium or salt substitutes high in potassium
spironolactone therapeutic class
Antihypertensive, drug for edema
furosemide therapeutic class
Drug for heart failure, hypertension
furosemide pharmacological class
Loop diuretic
furosemide indications
Heart failure, renal failure, hepatic cirrhosis, pulmonary edema, edema, HTN
furosemide MOA
Inhibits reabsorption of sodium and chloride in the ascending loop of Henle. Results in increased excretion of sodium, potassium, chloride, calcium, magnesium, and water
furosemide adverse effects
Dehydration, hypotension (low BP), electrolyte depletion (especially K+ and Mg), renal impairment, ototoxicity (higher doses, rapid IV administration)
furosemide nursing implications
Monitor urine output, BP, creatinine, K+, Mg (may require electrolyte replacement)
Avoid taking at bedtime
Educate patients on importance of monitoring lab work and BP
Rise slowly when getting up (orthostasis)
Older adults at risk for falls
Related to sulfonamides; watch for cross-sensitivity
Avoid using with other nephrotoxic or ototoxic drugs
If taking digoxin, monitor for toxicity if hypokalemic (low potassium level)
hydrochlorothiazide therapeutic class
Antihypertensive, Drug for edema
hydrochlorothiazide pharmacological class
Thiazide diuretic
hydrochlorothiazide indications
Mild to moderate HTN
hydrochlorothiazide MOA
Affects sodium reabsorption at the distal renal tubule, causing increased excretion of sodium and chloride
hydrochlorothiazide adverse effects
Electrolyte imbalances (dec. K+, Na, Mg), hypotension, vertigo, renal impairment, hyperglycemia in diabetic patients
hydrochlorothiazide nursing implications
Monitor BP, urine output, electrolytes, renal function, administer in morning. Less effective than loop diuretics
lisinopril therapeutic class
drug for HTN, heart failure, MI prevention
lisinopril pharmacologic class
ACE inhibitor
lisinopril indications
HTN, heart failure, acute MI
lisinopril MOA
prevents conversion of angiotensin 1 to angiotensin 2, decreases vasoconstriction and aldosterone secretion
lisinopril adverse effects
orthostatic hypotension, dizziness, headache, persistent dry cough, renal impairment, hyperkalemia, angioedema
lisinopril nursing considerations
discontinue if pregnant (teratogen), patient education (signs of hypotension, angioedema, avoid high sodium and high potassium foods, first dose phenomenon) monitor potassium and renal function (creatinine)
diltiazem therapeutic class
antihypertensive, abtianginal, antiarrhythmic
diltiazem pharmacologic class
calcium channel blocker
diltiazem indications
HTN, angina, tachyarrhythmias
diltiazem MOA
blocks transport of calcium into myocardial and vascular smooth muscle cells
diltiazem contraindications
heart block, shock
diltiazem adverse effects
hypotension, bradycardia, heart failure symptoms, headache, fatigue, n/v, arrhythmias
diltiazem nursing considerations
monitor BP, HR, ECG, can be given PO or IV, do not crush extended release tablet, patient education
beta blockers indications
HTN, heart failure, arrhythmias, MI, many non-cardiovascular uses as well
beta blockers MOA
block beta receptor site, resulting in decreased HR and myocardial contractility, which in turn decreases BP and myocardial oxygen demand
beta blockers adverse effects
bradycardia, hypotension, dizziness, fatigue/lethargy, decreased sexual ability, depression, worsening heart failure symptoms, bronchoconstriction
beta blockers nursing implications
monitor HR and BP, don’t stop medication abruptly, may mask symptoms of hypoglycemia, have patient report dizziness, lightheadedness, avoid in patients with asthma
beta blockers black box warning
clients with CAD, don’t stop abruptly
alpha 1 adrenergic blocker indications
HTN, benign prostate hypertrophy
alpha 1 adrenergic blocker MOA
block the a1 adrenergic receptor, resulting in vasodilation and relaxation of smooth muscles in the prostate
alpha 1 adrenergic blocker adverse effects
orthostatic hypotension, dizziness/drowsiness, headache, fatigue, syncope, first does phenomenon
alpha 1 adrenergic blocker nursing implications
take at night to avoid dizziness/drowsiness, rise slowly when getting up
alpha 2 adrenergic agonists indications
HTN
alpha 2 adrenergic agonists MOA
stimulating a2 adrenergic receptors results in decreased sympathetic response from the CNS, causing vasodilation and decreased BP
alpha 2 adrenergic agonists adverse effects
CNS depression, dizziness/ drowsiness, orthostatic hypotension
alpha 2 adrenergic agonists nursing implications
do not stop abruptly, rotate patch site weekly
vasodilators indications
hypertensive crisis (> 180/120), during or post-cardiac surgery
vasodilators MOA
relaxation of venous and arterial smooth muscle, leading to vasodilation and decreased peripheral resistance
vasodilators adverse effects
flushing, headache, n/v, cyanide and thiocyanate toicity
vasodilators nursing implications
administered as IV, rapid onset and short half life (2 min), monitor BP, HR, monitor for cyanide/thiocyanate toxicity, transition to oral therapy ASAP
therapeutic class of digoxin
drug for heart failure
pharmacologic class of digoxin
cardiac glycoside
indications of digoxin
heart failure, atrial fibrillation, atrial flutter
MOA of digoxin
increases intracellular calcium leading to positive inotropic effect, decreases conduction through SA and AV nodes leading to a negative chronotrophic effect and increased diastolic filling time
adverse effects of digoxin
bradycardia, arrhythmias, fatigue, N/V, blurred/yellow vision (Sign of toxicity), increased risk of toxicity when hypokalemic
nursing considerations of digoxin
loading dose followed by daily maintenance dose (IV or PO), monitor drug levels (narrow therapeutic range), check apical pulse for one minute before administering
carvedilol therapeutic class
antihypertensive, drug for heart failure
carvedilol pharm. class
beta-blocker
carvedilol MOA
Blocks stimulation of beta1, beta2, and alpha1 adrenergic receptors, leading to decreased heart rate and BP
carvedilol indications
HTN, heart failure, MI
carvedilol ADRs
Dizziness, fatigue, depression, bradycardia, weakness, erectile dysfunction, heart failure, bronchospasm/wheezing, diarrhea, hyperglycemia
carvedilol other consider.
Nursing consid: Monitor BP, HR, weight, signs of worsening heart failure, glucose levels, use with caution in patients with asthma, client eduation (do not stop medication abruptly, monitor BP and HR, change position slowly)
hydralazine pharm. class
vasodilator
hydralazine therapeutic class
antihypertensive
hydralazine MOA
Arteriolar vasodilation leading to decreased BP and afterload
hydralazine indications
HTN, heart failure unresponsive to other therapies (off-label)
hydralazine ADRs
Headache, N/V, reflex tachycardia, lupus-like symptoms (with higher doses, rare)
hydralazine nursing considerations
monitor BP, educate patient to notify provider if lupus-like symptoms develop, take 3-4 times daily, can lead to compliance issues
milrinone therapeutic class
inotrope
milrinone pharmacologic class
phosphodiesterase inhibitor
milrinone indications
acute, decomposed HF (short term therapy)
milrinone MOA
blocking of phosphodiesterase enzyme leads to increased cardiac contractility (positive inotropic effect) and vasodilation (decreased preload and after load). this leads to increased cardiac output
milrinone ADRs
hypotension, arrhythmias (10% risk) angina
milrinone nursing implications
administered as continuous IV infusion, short half life, monitor BP, cardiac output/index, ECG
digoxin therapeutic class
drug for HF
digoxin pharm. class
Cardiac glycoside
digoxin indications
Heart failure, atrial fibrillation, atrial flutter
digoxin MOA
Increases intracellular calcium leading to positive inotropic effect. Decreases conduction through SA and AV nodes, leading to a negative chronotropic effect and increased diastolic filling time
digoxin ADRs
Bradycardia, arrhythmias, fatigue, N/V, blurred/yellow vision (sign of toxicity); increased risk of toxicity when hypokalemic
digoxin other consider.
Nursing consid: Loading dose, followed by daily maintenance dose (IV or PO), monitor drug levels (narrow therapeutic range), check apical pulse for one minute before administering (generally hold for HR <60), antidote is digoxin immune fab (Digibind)
hydralazine other consider.
nursing consid:Monitor BP, educate patient to notify provider if lupus-like symptoms develop, take 3-4 times daily; can lead to compliance issues
milrinone therapeutic class
inotrope
milrinone pharm. class
phosphodiesterase inhibitor
milrinone indications
Acute, decompensated heart failure (short term therapy)
milrinone MOA
Blocking of phosphodiesterase enzyme leads to increased cardiac contractility (positive inotropic effect) and vasodilation (decreased preload and afterload). This leads to increased cardiac output
milrinone ADRs
Hypotension, arrhythmias (10% risk), angina (chest pain)
milrinone other consider.
Nursing Imp: Administered as continuous IV infusion; short half-life; monitor BP, cardiac output/index, ECG
oxymetazoline (Afrin) contraindications
those with HTN, thyroid disorders, diabetes and heart disease should consult with provider
oxymetazoline (Afrin) nursing implications
instruct clients not to use for more than 3 days.
heparin therapeutic class
anticoagulant
heparin pharmacologic class
Indirect thrombin inhibitor
heparin indications
Prevent formation of clots; often used prophylactically
heparin MOA
The binding of heparin to antithrombin III blocks clotting through the inactivation of Factor X and inhibition of prothrombin’s conversion to thrombin (thrombin inhibitor)
heparin adverse effects
Bleeding, heparin induced thrombocytopenia (HIT)
*Heparin Induced Thrombocytopenia leads to a prothrombic stated (increased risk of clotting) and the development of thrombocytopenia (a low platelet count)
heparin other consider.
Administered SQ (for prophylaxis) or IV Monitor for bleeding Monitor platelets (for HIT) Monitor PTT (Partial Thromboplastin Time Goal 1.5-2.5 x normal value May also monitor anti-Factor Xa levels Protamine sulfate is antidote Half life is ~1 hour (for IV)
warfarin therapeutic class
anticoagulant
warfarin pharm. class?
vitamin K antagonist
warfarin indications
Prevent formation of clots; can be used prophylactically
warfarin MOA
Blocks the generation of vitamin K, thereby inhibiting synthesis of vitamin K dependent clotting factors
warfarin ADRs
Bleeding, skin necrosis (rare)
warfarin other consider.
Given orally at same time each day
Takes several days to reach maximum effect (overlaps with heparin therapy)
Monitor PT/INR (Prothrombin Time/Internationalized Ratio)
goal is typically INR of 2-3
INR must be measured regularly on outpatient basis as well
Educate clients about bleeding precautions
Contraindicated in pregnancy
Multiple drug-drug and drug-diet interactions (consistency is key)
amiodarone therap. class?
antidysrhythmic
amiodarone pharm. class?
potassium channel blocker
amiodarone indications
Treatment of life threatening ventricular dysrhythmias, treatment of atrial dysrhythmias (off-label)
amiodarone MOA
Prolongs action potential and refractory period, slowing the heart rate. Decreases peripheral vascular resistance through vasodilation
amiodarone ADRs
Worsening of dysrhythmias, pulmonary toxicity, bradycardia, hypotension, N/V, dizziness, fatigue, blue discoloration of skin, increased liver enzymes, effect on thyroid function, photosensitivity, tremors, blurry vision
amiodarone other consider.
Interactions Multiple drug interactions- increases drug levels of digoxin, warfarin, and carvedilol (just to name a few)
Nursing Considerations Requires loading dose, ECG monitoring if giving IV, monitor HR and BP, assess for signs of pulmonary toxicity (thorough respiratory assessment), monitor liver and thyroid function, avoid grapefruit juice, can be given PO or IV, prolonged half-life (several weeks), pregnancy category D